19:46:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-20 Ordinarie utdelning TOL 0.00 SEK
2024-06-19 Årsstämma 2024
2024-05-20 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-06-08 Ordinarie utdelning TOL 0.00 SEK
2023-06-07 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-08-26 Kvartalsrapport 2022-Q2
2022-06-07 Ordinarie utdelning TOL 0.00 SEK
2022-06-03 Årsstämma 2022
2022-05-06 Kvartalsrapport 2022-Q1
2022-02-25 Bokslutskommuniké 2021
2021-10-29 Kvartalsrapport 2021-Q3
2021-09-16 Extra Bolagsstämma 2021
2021-08-27 Kvartalsrapport 2021-Q2
2021-06-07 Ordinarie utdelning TOL 0.00 SEK
2021-06-04 Årsstämma 2021
2021-05-06 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-02 Kvartalsrapport 2020-Q3
2020-08-10 Kvartalsrapport 2020-Q2
2020-06-15 Ordinarie utdelning TOL 0.00 SEK
2020-06-12 Årsstämma 2020
2020-05-11 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-18 Kvartalsrapport 2019-Q3
2019-08-26 Kvartalsrapport 2019-Q2
2019-06-14 Ordinarie utdelning TOL 0.00 SEK
2019-06-13 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-26 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-18 Ordinarie utdelning TOL 0.00 SEK
2018-06-15 Årsstämma 2018
2018-05-11 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2018-02-05 Extra Bolagsstämma 2017
2017-12-08 Extra Bolagsstämma 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-06-12 Ordinarie utdelning TOL 0.00 SEK
2017-06-09 Årsstämma 2017
2017-05-12 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-06-10 Årsstämma 2016
2016-05-25 Kvartalsrapport 2016-Q1
2016-05-11 Ordinarie utdelning TOL 0.00 SEK
2016-02-24 Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Toleranzia är ett forskningsbolag. Bolagets affärsinriktning återfinns inom utveckling av läkemedelskandidater för behandling av autoimmuna sjukdomar. Bolaget har utvecklat en plattformsteknologi med fokus mot muskelsjukdomen myastenia gravis. Utöver har teknologin använts i övriga områden som diabetes och multipel skleros. Forskningssamarbeten sker i samarbete med externa partners inom arbetsområdet. Huvudkontoret ligger i Göteborg.
2023-01-12 09:05:00

Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023.

The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on June 3, 2022, consists of:
 
-           Carl-Johan Spak, appointed by Flerie Invest AB
-           Klementina Österberg, appointed by GU Ventures AB
-           Sören Christensen

The Chairman of the Board of Directors, Ann-Charlotte Rosendahl, is the convener of the Nomination Committee.
 
The Nomination Committee shall, before the Annual General Meeting 2023, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, the election of auditors, the determination of fees and matters pertaining thereto.
 
Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting on June 7, 2023, can do so via e-mail to info@toleranzia.com (label the e-mail with ‘Nomination Committee) not later than April 15, 2023.
 
Information about the Nomination Committee’s work and the instruction to the Nomination Committee can be found on the company website under the section for Investors/Corporate governance. The Nomination Committee’s proposal will be presented in the summon to the Annual General Meeting 2023 and on the company’s web page: www.toleranzia.com.
 
For further information about the Nomination Committee, please contact: Ann-Charlotte Rosendahl, Chairman of the Board of Directors, Toleranzia AB.
E-mail: ann-charlotte.rosendahl@toleranzia.com
Phone: +46 732096405
 
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.